Movement Disorders (revue) - Exploration (Accueil)

Index « Keywords » - entrée « Substantia Nigra (drug effects) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Substantia Nigra (cytology) < Substantia Nigra (drug effects) < Substantia Nigra (embryology)  Facettes :

List of bibliographic references indexed by Substantia Nigra (drug effects)

Number of relevant bibliographic references: 52.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000721 (2013) David Dybdal [États-Unis] ; Patrick A. Forcelli ; Mark Dubach ; Michael Oppedisano ; Angela Holmes ; Ludise Malkova ; Karen GaleTopography of dyskinesias and torticollis evoked by inhibition of substantia nigra pars reticulata.
000905 (2013) Jose A. Obeso ; J. Guridi ; A. Nambu ; A R CrossmanMotor manifestations and basal ganglia output activity: the paradox continues.
001579 (2011) Elisa Garbayo [Espagne] ; Eduardo Ansorena [Espagne] ; Jose Luis Lanciego [Espagne] ; María Jose Blanco-Prieto [Espagne] ; María S. Aymerich [Espagne]Long‐term neuroprotection and neurorestoration by glial cell‐derived neurotrophic factor microspheres for the treatment of Parkinson's disease
001E74 (2010) Pauline Belujon [États-Unis] ; Daniel J. Lodge [États-Unis] ; Anthony A. Grace [États-Unis]Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment
002784 (2008) C. Warren Olanow [États-Unis]Levodopa/dopamine replacement strategies in Parkinson's disease—Future directions
002925 (2008) Mario Zappia [Italie] ; Aldo Quattrone [Italie]Continuous dopaminergic stimulation: Is it the answer to the motor complications of levodopa?
002D65 (2007) Martin Köllensperger [Autriche] ; Nadia Stefanova [Autriche] ; Markus Reindl [Autriche] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche]Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy
003837 (2005) Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Mikko Kuoppamaki [Royaume-Uni, Finlande] ; C. Warren Olanow [États-Unis] ; Peter Jenner [Royaume-Uni]Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates
003897 (2005) Evžen Růži Ka [République tchèque] ; Dušan Urgošík [République tchèque] ; Robert Jech [République tchèque] ; Jan Roth [République tchèque] ; Josef Vymazal [République tchèque] ; Petr Me [République tchèque] ; Vilibald Vladyka [République tchèque]Hemiparkinsonism and levodopa‐induced dyskinesias after focal nigral lesion
003D76 (2004) Guido Alves [Norvège] ; Martin Kurz [Norvège] ; Stein A. Lie [Norvège] ; Jan P. Larsen [Norvège]Cigarette smoking in Parkinson's disease: Influence on disease progression
004007 (2003) Peter Teismann [États-Unis] ; Kim Tieu [États-Unis] ; Oren Cohen [États-Unis] ; Dong-Kug Choi [États-Unis] ; Du Chu Wu [États-Unis] ; Daniel Marks [États-Unis] ; Miquel Vila [États-Unis] ; Vernice Jackson-Lewis [États-Unis] ; Serge Przedborski [États-Unis]Pathogenic role of glial cells in Parkinson's disease
004038 (2003) Michael Orth [Royaume-Uni] ; Sarah J. Tabrizi [Royaume-Uni]Models of Parkinson's disease
004108 (2003) Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Eleni Maratos [Royaume-Uni] ; Peter Jenner [Royaume-Uni]Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure
004374 (2002) Maria C. Obinu [France] ; Michel Reibaud [France] ; Véronique Blanchard [France] ; Saliha Moussaoui [France] ; Assunta Imperato [France]Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence
004693 (2001) Oum-Kaltoum Hassani [France] ; Mireille Mouroux [France] ; Georg Andrees Bohme [France] ; Jean-Marie Stutzmann [France] ; Jean Féger [France]Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6‐OHDA lesion in the rat brain
004745 (2001) Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni]Neural mechanisms underlying peak‐dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan
004836 (2001) Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie]Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease
004845 (2001) Krishna P. Datla [Royaume-Uni] ; Stavia B. Blunt [Royaume-Uni] ; David T. Dexter [Royaume-Uni]Chronic L‐DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6‐OHDA or FeCl3 nigrostriatal lesions
004850 (2001) Hélène Turmel [France] ; Andreas Hartmann [France] ; Karine Parain [France] ; Aicha Douhou [France] ; Anu Srinivasan [États-Unis] ; Yves Agid [France] ; Etienne C. Hirsch [France]Caspase‐3 activation in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated mice
004976 (2000) Donato A. Di Monte [États-Unis] ; Alison Mccormack [États-Unis, Suède] ; Giselle Petzinger [États-Unis] ; Ann Marie Janson [États-Unis, Suède] ; Maryka Quik [États-Unis] ; William J. Langston [États-Unis]Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model
004A02 (2000) Leo Verhagen Metman [États-Unis] ; Spiridon Konitsiotis [États-Unis] ; Thomas N. Chase [États-Unis]Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Substantia Nigra (drug effects)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Substantia Nigra (drug effects)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Substantia Nigra (drug effects)
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024